Innate Pharma (IPHA) Enterprise Value (2017 - 2025)

Innate Pharma (IPHA) has reported Enterprise Value for 9 consecutive years, with -$39.0 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value rose 57.52% year-over-year to -$39.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.0 million (up 57.52% YoY) and the FY2025 annual result came in at -$39.0 million, up 57.52% from the prior year.
• Enterprise Value improved to -$39.0 million in Q4 2025 per IPHA's latest filing, from -$68.3 million in the prior quarter.
• Over the last five years, Enterprise Value for IPHA reached as high as -$39.0 million in Q4 2025 and fell as low as -$140.4 million in Q2 2022.
• A 5-year average of -$103.8 million and a median of -$104.8 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2021 — Enterprise Value surged 99.91% — and 2022, when it slipped 3.38%.
• Year by year, Enterprise Value stood at -$136.4 million in 2021, then grew by 15.31% to -$115.5 million in 2022, then gained by 8.9% to -$105.2 million in 2023, then gained by 12.64% to -$91.9 million in 2024, then soared by 57.52% to -$39.0 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$39.0 million, -$68.3 million, and -$91.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.